ClinicalTrials.gg
Not yet recruitingNCT07791199Updated Sep 3, 2026

Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

A Phase 3 interventional study of Deucravacitinib in Systemic Lupus Erythematosus, Sjögren's Disease and Psoriasis, sponsored by Bristol-Myers Squibb. Not yet recruiting. Open to participants aged 4 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,300
Allocation
Not applicable
Ages
4 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb — 5 open to participants now, 9 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Bristol-Myers Squibb.

Planned enrollment
Largest of 19
2,300 · median 125
Started
2026
with 2 others
Phase 3
3 of 20
1 open now
Registered
19th of 20
by date

Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 19th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

5 of the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 4 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.

03

Conditions studied

  • Systemic Lupus Erythematosus
  • Sjögren's Disease
  • Psoriasis
  • Psoriatic Arthritis

Keywords

  • SLE
  • SJD
  • SJS
  • PSO
  • PSA
  • POETYK
  • POETYK-1
  • POETYK-2
  • POETK-SJS
  • jPSA
  • Pediatric
  • Juvenile
  • Deucravacitinib
  • SOTYKTU
04

Who can participate

Ages eligible
4 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have completed qualifying parent study through the protocol required treatment period. Qualifying studies include IM011-246, IM011-247, IM011-1069, IM011-126, IM011-1128, and IM011-1071.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have any disease or medical condition that, in the opinion of the physician, would make them unsuitable for this protocol, would interfere with the interpretation of their safety or considered unsuitable by the physician for any other reason.

Other protocol-defined inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,300 participants (estimated)

Study arms

  • Experimental
    Deucravacitinib Arm

    Drug: Deucravacitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants treated

    Time frame: Up to approximately 28 days after last dose of deucravacitinib

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Oct 2030, 46 months later.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Aug 27, 2026
StartEst.
Dec 31, 2026
Primary completionEst.
Oct 31, 2030
CompletionEst.
Oct 31, 2030
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07791199
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Oct 31, 2030 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Sep 3, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion